|Day Low/High||17.16 / 17.43|
|52 Wk Low/High||16.63 / 35.16|
The Saudi Arabian economy needs to rebalance away from oil.
The Cambridge, Mass.-based company and Mylan said that M834, a proposed biosimilar of Orencia (abatacept), did not achieve its primary pharmacokinetic endpoints in a Phase 1 study.
Yesterday I reemphasized that Teva should be avoided. Today Mylan was hit by an apparent extension of a generic drug pricing collusion probe. Mylan's shares have fallen by nearly seven precnet in the morning session.
On Wednesday I explained why I would avoid Teva Pharmaceutical Industries : I know by the Comments Section that there has been a lot of bottom fishing in Teva (TEVA) . I had done a few hours of research on the company over the last months and passed...
The three major indexes closed at record highs, the Dow for its third day in a row, the Nasdaq its fourth, and the S&P 500 its fifth.
Risk is harder to gauge than a price target after a gap like the one we have on MYL.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks.
Mylan scored FDA approval for a generic version of Teva Pharmaceuticals' multiple sclerosis drug, Copaxone.
The Israeli pharma company Teva has established a rich history since its founding in 1901. Can it continue to survive as it faces one challenge after another?
The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.
Mylan's drug approval announced this morning is a big negative for Teva Pharmaceutical Industries and likely will result in a $3 to $5 drop in Allergan's shares in the early going.
"If you need a friend, get a dog."
13 people are dead and 100 injured in the terror attack at a popular tourist spot in Barcelona.
Strong quarterly performances from Target Corp. and Urban Outfitters Inc. inspired broader retail gains.
Wall Street pulled lower mid-week on worries over rising tensions between the U.S. and North Korea.
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending stocks.
I would look to begin trading it on the long side above $160.
Defense stocks lifted Wall Street to begin the week after Donald Trump's first leg of a trip abroad resulted in billions of dollars' worth of deals.
K-Mart pharmacies lowered the cost of its generic epinephrine auto-injector pens to $199.99
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
Kaleo's EpiPen compeitor the Auvi-Q was released today.